Business Wire

DC-DALBERG-ADVISORS

25.3.2024 06:01:31 CET | Business Wire | Press release

Share
Dalberg Awarded 5-Year Contract to Strengthen United States Agency for International Development's (USAID) Work With the Private Sector

Dalberg Advisors (https://Dalberg.com/) has announced the award of the Private Sector Engagement Strategic Collaboration and Leading-Edge Engagement (“PSE SCALE”) program, a framework agreement of advisory services that will support the U.S. Agency for International Development (USAID: https://www.USAID.gov/) to engage the private sector to achieve development and humanitarian outcomes. Through the five-year, $99.1-million contract, Dalberg and its partners will support USAID to accelerate private sector partnerships around the world and transform the Agency’s capacity to work with the private sector.

PSE SCALE is an extension of over 20 years of efforts by USAID to increasingly partner and invest with the private sector to achieve the Agency’s development and humanitarian goals. It represents the flagship mechanism to upgrade USAID’s capacity to work with the private sector and will provide a range of technical and advisory services to USAID Missions and operating units seeking to expand or accelerate private sector engagement. Activities include support for strategy development, organizational effectiveness, workforce development, partnership facilitation, market research and more. In an increasingly complex global environment, the objective of this work is to position USAID as a capable and vital partner to companies seeking to drive growth and innovation in new markets, reduce risk, and advance sustainability goals.

Dalberg and a consortium of partners— 60 Decibels (https://60Decibels.com/), CrossBoundary (https://CrossBoundary.com/), Vera Solutions (https://VeraSolutions.org/), and Social Solutions International (https://www.SocialSolutions.biz/)—will provide a comprehensive and integrated suite of services that are delivered on-demand and in response to needs and opportunities in any operating unit across USAID. The team collectively brings decades of experience in serving clients globally across the public and private sectors on a wide range of sustainable development issues.

“Dalberg is thrilled to be supporting USAID in deepening its collaboration with the private sector. Our experience and local networks across markets in Africa, Asia, and Latin America makes Dalberg a natural partner for USAID,” said Gaurav Gupta, Dalberg’s Global Managing Partner. “And with over 1,100 clients across the public and private sectors, we have a long track record of designing successful cross-sector partnerships that help all parties to advance their goals.”

Distributed by APO Group on behalf of Dalberg Advisors.

Download image: https://apo-opa.co/4cw4lVk (Illustration of multi-sectorial activities)

About Dalberg Advisors:

Dalberg Advisors is a strategic advisory firm that combines private sector strategy skills and analytical capabilities with deep knowledge and networks across emerging and frontier markets. Dalberg works actively across the public, private, and philanthropic sectors to help clients achieve their goals and has over 500 employees across 25 locations in Africa, Asia-Pacific, Latin America, Europe, and the U.S. Dalberg Advisors is part of the Dalberg Group, which comprises a collection of mission-driven enterprises—Dalberg Advisors, Dalberg Data Insights, Dalberg Design, Dalberg Media, Dalberg Implement, Dalberg Research—and the not-for-profit, Dalberg Catalyst.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240324686686/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye